What does CELYNTRA THERAPEUTICS do?

CELYNTRA THERAPEUTICS is a wholesaler in Mont-Saint-Guibert. Public Limited, started on 19 November 2019, 1 establishment.

What is the address of CELYNTRA THERAPEUTICS?

The registered office of CELYNTRA THERAPEUTICS is located at Rue Edouard Belin 2, 1435 Mont-Saint-Guibert.

Is CELYNTRA THERAPEUTICS still active?

Yes. According to the CBE (29 October 2026) CELYNTRA THERAPEUTICS is active, legal situation “Normale toestand”, started on 19 November 2019.

Is CELYNTRA THERAPEUTICS registered on Peppol?

Yes, CELYNTRA THERAPEUTICS is registered on the Peppol network with ID 0208:0737829015.

What is the enterprise number of CELYNTRA THERAPEUTICS?

The enterprise number of CELYNTRA THERAPEUTICS is BE0737829015.

When was CELYNTRA THERAPEUTICS founded?

CELYNTRA THERAPEUTICS was founded on 19 November 2019.

Who are the directors of CELYNTRA THERAPEUTICS?

According to the 2025 annual accounts, the directors of CELYNTRA THERAPEUTICS are: Jason Conner.

Is CELYNTRA THERAPEUTICS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 November 2019; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did CELYNTRA THERAPEUTICS make in 2025?

CELYNTRA THERAPEUTICS recorded a loss after taxes of € 3,065,141 in financial year 2025.

What is the revenue of CELYNTRA THERAPEUTICS?

As a small company, CELYNTRA THERAPEUTICS is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 560,992.

How much does an employee at CELYNTRA THERAPEUTICS earn?

The average wage cost per full-time employee at CELYNTRA THERAPEUTICS was € 100,200 in 2025: staff costs of € 1.3 million for 12.7 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does CELYNTRA THERAPEUTICS have?

According to the 2025 annual accounts, CELYNTRA THERAPEUTICS has 12.7 full-time equivalents (FTE).

CELYNTRA THERAPEUTICS (Public Limited)

Dossier CELYNTRA THERAPEUTICS, printed on 29 October 2026 from databakkes.be/en/0737829015/celyntra-therapeutics. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 12 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

CELYNTRA THERAPEUTICS from Mont-Saint-Guibert, company number BE0737829015, closed financial year 2025 with a result of € -3.1 million after tax. For that financial year CELYNTRA THERAPEUTICS recorded a gross margin of € 560,992 and equity of € -9.6 million. Compared with financial year 2024, the result moved from € -6.4 million to € -3.1 million. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 10, 2026.

What it is worth Caution

€ -9.6 million

▼ € 2.7 million vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -3.1 million

▲ 52 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 445,046

▲ 207% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -10.4 million.

People and assets in 2025

Full-time equivalents

12.7

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 1.3 million

▲ 12% vs 2024

€ 100,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 6.8 million

▲ 62% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 191,496

▲ 15% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -99,228 Gross margin 2022: € -99,228 First fiscal year in the series	€ -837,405 Gross margin 2023: € -837,405 ▼ € 738,177 vs 2022 (€ -99,228) Unfavourable step	€ -3,849,515 Gross margin 2024: € -3,849,515 ▼ € 3 million vs 2023 (€ -837,405) Unfavourable step	€ 560,992 Gross margin 2025: € 560,992 ▲ € 4.4 million vs 2024 (€ -3,849,515) Favourable step	▲ € 4.4 million
Profit after taxes	€ -123,119 Profit after taxes 2022: € -123,119 First fiscal year in the series	€ -951,235 Profit after taxes 2023: € -951,235 ▼ € 828,115 vs 2022 (€ -123,119) Unfavourable step	€ -6,394,036 Profit after taxes 2024: € -6,394,036 ▼ € 5.4 million vs 2023 (€ -951,235) Unfavourable step	€ -3,065,141 Profit after taxes 2025: € -3,065,141 ▲ € 3.3 million vs 2024 (€ -6,394,036) Favourable step	▲ € 3.3 million
Equity	€ -1,747,700 Equity 2022: € -1,747,700 First fiscal year in the series	€ -598,935 Equity 2023: € -598,935 ▲ € 1.1 million vs 2022 (€ -1,747,700) Favourable step	€ -6,852,391 Equity 2024: € -6,852,391 ▼ € 6.3 million vs 2023 (€ -598,935) Unfavourable step	€ -9,597,948 Equity 2025: € -9,597,948 ▼ € 2.7 million vs 2024 (€ -6,852,391) Unfavourable step	▼ € 2.7 million
Total debts	€ 1,852,691 Total debts 2022: € 1,852,691 First fiscal year in the series	€ 3,345,624 Total debts 2023: € 3,345,624 ▲ 81% vs 2022 (€ 1,852,691) Unfavourable step	€ 14,779,303 Total debts 2024: € 14,779,303 ▲ € 11.4 million vs 2023 (€ 3,345,624) Unfavourable step	€ 17,642,013 Total debts 2025: € 17,642,013 ▲ 19% vs 2024 (€ 14,779,303) Unfavourable step	▲ 19%
Cash	€ 57,602 Cash 2022: € 57,602 First fiscal year in the series	€ 2,097,313 Cash 2023: € 2,097,313 ▲ € 2 million vs 2022 (€ 57,602) Favourable step	€ 144,794 Cash 2024: € 144,794 ▼ 93% vs 2023 (€ 2,097,313) Unfavourable step	€ 445,046 Cash 2025: € 445,046 ▲ 207% vs 2024 (€ 144,794) Favourable step	▲ 207%
Retained profit	€ -1,809,200 Retained profit 2022: € -1,809,200 First fiscal year in the series	€ -951,235 Retained profit 2023: € -951,235 ▲ € 857,965 vs 2022 (€ -1,809,200) Favourable step	€ -7,345,271 Retained profit 2024: € -7,345,271 ▼ € 6.4 million vs 2023 (€ -951,235) Unfavourable step	€ -10,410,412 Retained profit 2025: € -10,410,412 ▼ € 3.1 million vs 2024 (€ -7,345,271) Unfavourable step	▼ € 3.1 million
Balance sheet total	€ 104,991 Balance sheet total 2022: € 104,991 First fiscal year in the series	€ 2,746,689 Balance sheet total 2023: € 2,746,689 ▲ € 2.6 million vs 2022 (€ 104,991) Unchanged	€ 7,926,911 Balance sheet total 2024: € 7,926,911 ▲ 189% vs 2023 (€ 2,746,689) Unchanged	€ 8,199,065 Balance sheet total 2025: € 8,199,065 ▲ 3% vs 2024 (€ 7,926,911) Unchanged	▲ 3%
Employees (FTE)	-	-	12.7 Employees (FTE) 2024: 12.7 First fiscal year in the series	12.7 Employees (FTE) 2025: 12.7 Unchanged (12.7) Unchanged

Key figures of CELYNTRA THERAPEUTICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CELYNTRA THERAPEUTICS?

What happened at CELYNTRA THERAPEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2027 Jason Conner stepped down as director. NBB
Jun 10, 2026 New annual accounts for financial year 2025: loss of € 3.1 million. Source: NBB ↗
2026 Jason Conner became a director. NBB
Nov 19, 2019 New establishment in Mont-Saint-Guibert. KBO
Nov 19, 2019 Start of the company according to the CBE. KBO

In short

From € 123,119 loss in 2022 to € 3.1 million loss in 2025.

On average € 44,200 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Ncardia Holding 0%

The stake of Ncardia Holding comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

CELYNTRA THERAPEUTICS

The shares are held by Ncardia Holding (0%).

Directors

According to the 2025 annual accounts

Jason Conner

Managing director

Also active at: Ncardia Holding, Cellistic

since 2026 · until 2027

Shareholders

Ncardia Holding

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Edouard Belin 2

1435 Mont-Saint-Guibert

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

Ncardia Holding same network

€ -1.5 million gross margin · 2025

Cellistic same network

€ 8.6 million revenue · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0737.829.015
VAT number: BE 0737.829.015
Registered office: Rue Edouard Belin 2, 1435 Mont-Saint-Guibert
Names & denominations: CELYNTRA THERAPEUTICS
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 19 November 2019
Peppol: Active · Active since 27 Nov 2025
Activities · NACE: Groothandel in farmaceutische en medische artikelen

View on CBE Public ↗ Annual accounts (NBB) ↗